Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees

Journal of Virology

Volumn 73, Issue 4, 1999, Pages 3438-3442

  Whitehead, Stephen S ^a   Bukreyev, Alexander ^a   Teng, Michael N ^a   Firestone, Cai Yen ^a   Claire, Marisa St ^b   Elkins, William R ^a   Collins, Peter L ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BIOQUAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; VIRUS VACCINE;

ARTICLE; CHIMPANZEE; DRUG SAFETY; GENE DELETION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHINORRHEA; VACCINE PRODUCTION; VIRUS ATTENUATION; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0032978732     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.4.3438-3442.1999     Document Type: Article

References (35)

1. Atreya, P. L., M. E. Peeples, and P. L. Collins. 1998. The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. J. Virol. 72:1452-1461.
2. Bouchard, M. J., D. H. Lam, and V. R. Racaniello. 1995. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69:4972-4978.
3. Bukreyev, A., S. S. Whitehead, B. R. Murphy, and P. L. Collins. 1997 Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982.
4. Coates, H. V., D. W. Ailing, and R. M. Chanock. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:299-313.
5. Collins, P. L., M. G. Hill, E. Camargo, H. Grosfeld, R. M. Chanock, and B. R. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA 92:11563-11567.
6. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1352. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
7. Collins, P. L., R. H. Purcell, W. T. London, L. A. Lawrence, R. M. Chanock, and B. R. Murphy. 1990. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8:164-168.
8. Crowe, J. E., Jr., P. T. Bui, A. R. Davis, R. M. Chanock, and B. R. Murphy. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790.
9. Crowe, J. E., Jr., P. T. Bui, W. T. London, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691-699.
10. Crowe, J. E., Jr., C. Y. Firestone, S. S. Whitehead, P. L. Collins, and B. R. Murphy. 1996. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 13:269-273.
11. Dowell, S. F., L. J. Anderson, H. E. Gary, Jr., D. D. Erdman, J. F. Ploufe, T. M. File, Jr., B. J. Marston, and R. F. Breiman. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174:456-462.
12. Falsey, A. R., C. K. Cunningham, W. H. Barker, R. W. Kouides, J. B. Yuen, M. Menegus, L. B. Weiner, C. A. Bonville, and R. F. Betts. 1995. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:389-394.
13. Falsey, A. R., J. J. Treanor, R. F. Betts, and E. E. Walsh. 1992. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40:115-119.
14. Firestone, C. Y., S. S. Whitehead, P. L. Collins, B. R. Murphy, and J. E. Crowe, Jr. 1996. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology 225:419-422.
15. Friedewald, W. T., B. R. Forsyth, C. B. Smith, M. A. Gharpure, and R. M. Chanock. 1968. Low-temperature-grown RS virus in adult volunteers. JAMA 203:690-694.
16. Gilchrist, S., T. J. Torok, H. E. Gary, Jr., J. P. Alexander, and L. J. Anderson. 1994. National surveillance for respiratory syncytial virus. United States, 1985-1990. J. Infect. Dis. 170:986-990.
17. Hall, C. B., K. R. Powell, N. E. MacDonald, C. L. Gala, M. E. Menegus, S. C. Suffin, and H. J. Cohen. 1986. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 315:77-81.
18. Hall, S. L., A. Stokes, E. L. Tierney, W. T. London, R. B. Belshe, F. C. Newman, and B. R. Murphy. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:173-184.
19. Harrington, R. D., T. M. Hoolon, R. C. Hackman, G. A. Storch, B. Osborne, C. A. Gleaves, A. Benson, and J. D. Meyers. 1992. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J. Infect. Dis. 165:987-993.
20. Juhasz, K., S. S. Whitehead, C. A. Boulanger, C. Y. Firestone, P. L. Collins, and B. R. Murphy. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine, in press.
21. Juhasz, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:5814-5819.
22. La Via, W. V., M. I. Marks, and H. R. Stutman. 1992. Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention. J. Pediatr. 121:503-510.
23. Mills, J., J. E. Van Kirk, P. F. Wright, and R. M. Chanock. 1971. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J. Immunol. 107:123-130.
24. Mlinaric-Galinovic, G., A. R. Falsey, and E. E. Walsh. 1996. Respiratory syncytial virus infection in the elderly. Eur. J. Clin. Microbiol. Infect. Dis. 15:777-781.
25. Murphy, B. R., S. L. Hall, A. B. Kulkarni, J. E. Crowe, Jr., P. L. Collins, M. Connors, R. A. Karron, and R. M. Chanock. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13-36.
26. Murphy, B. R., E. J. Park, P. Gottlieb, and K. Subbarao. 1997 An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 15:1372-1378.
27. Snyder, M. H., R. F. Betts, D. DeBorde, E. L. Tierney, M. L. Clements, D. Herrington, S. D. Sears, R. Dolin, H. F. Maassab, and B. R. Murphy. 1988. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J. Virol. 62:488-495.
28. Tatem, J. M., C. Weeks-Levy, A. Georgiu, S. J. DiMichele, E. J. Gorgacz, V. R. Racaniello, F. R. Cano, and S. J. Mento. 1992. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J. Virol. 66:3194-3197.
29. Teng, M. N., and P. L. Collins. 1998. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce the NS2 protein. J. Virol. 73:466-473.
30. Tolpin, M. D., J. G. Massicot, M. G. Mullinix, H. W. Kim, R. H. Parrott, R. M. Chanock, and B. R. Murphy. 1981. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo. Virology 112:505-517.
31. Wendt, C. H., and M. I. Hertz. 1995. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin. Respir. Infect. 10:224-231.
32. Westrop, G. D., K. A. Wareham, D. M. A. Evans, G. Dunn, P. D. Minor, D. I. Magrath, F. Taffs, S. Marsden, M. A. Skinner, G. C. Schild, and J. W. Almond. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63:1338-1344.
33. Whitehead, S. S., C. Y. Firestone, P. L. Collins, and B. R. Murphy. 1998. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247:232-239.
34. Whitehead, S. S., K. Juhasz, C. V. Firestone, P. L. Collins, and B. R. Murphy. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J. Virol. 72:4467-4471.
35. Wright, P. F. Personal communication.